Caristo Diagnostics Applauds FDAs Historic Approval of Colchicine as a Breakthrough Anti- Inflammatory Treatment for Cardiovascular Disease
Friday, June 23, 2023
Caristo Diagnostics, a global leader in cardiac and vascular disease diagnostics and risk prediction, commends the recent FDA approval of colchicine as the first anti-inflammatory drug for cardiovascular disease. This landmark decision by the FDA recognizes the potential of colchicine in managing inflammation related to cardiovascular conditions.
Caristo Diagnostics is dedicated to driving innovation in the field of cardiovascular diagnostics, particularly in coronary inflammation detection and cardiovascular risk prediction based on Coronary Computed Tomography Angiography (CCTA). The company is committed to ensuring that every patient with coronary inflammation receives appropriate treatment, including the newly approved anti-inflammatory drug endorsed by the FDA.
In a press release by AGEPHA Pharma USA on June 20, it was announced that the FDA has approved LODOCO® (Colchicine 0.5 mg) as an anti-inflammatory treatment for adult patients with established atherosclerotic disease or multiple risk factors for cardiovascular disease. A comprehensive clinical trial, involving multiple countries, demonstrated that 0.5 mg colchicine, when added to high-intensity statins and other cardiovascular prevention therapies, significantly reduces the overall risk of cardiovascular death, spontaneous myocardial infarction, ischemic stroke, or ischemia-driven coronary revascularization by 31% compared to the placebo group.
The approval of colchicine by the FDA represents a significant advancement in addressing coronary inflammation, a major contributor to heart attacks. While current methods focus on measuring circulating inflammatory biomarkers such as C-reactive protein (CRP), Caristo Diagnostics' Ca-Ri Heart® technology employs advanced AI-driven techniques to analyze CCTA scans. This technology enables the detection and quantification of coronary artery inflammation through the innovative Fat Attenuation Index (FAI) Score. Identifying patients at high risk with coronary inflammation, independent of other clinical or CCTA features, is crucial to maximizing the benefits of newly approved anti-inflammatory drugs.
Caristo Diagnostics recognizes the importance of accurate assessment of inflammation and its impact on cardiovascular health. Their Ca-Ri Heart® technology goes beyond traditional biomarkers, such as CRP, by utilizing Coronary Computed Tomography Angiography-derived biomarkers, including anatomical high-risk plaque features and perivascular adipose tissue (PVAT). These advancements provide clinicians with a more precise and specific evaluation of inflammation and help prioritize treatment and monitoring strategies for optimal patient outcomes.